Lou Gehrig's Disease: A Global Strategic Business Report
San Jose, CA (PRWEB) March 24, 2010
Lou Gehrig's disease, also referred to as Amyotrophic Lateral Sclerosis (ALS) is one of the several orphan diseases in the neurodegenerative disease category. ALS is also known as Maladie de Charcot in France. In Australia and the UK, the disease is known as Motor Neuron Disease (MND). With around 7 people in 100,000 living with ALS worldwide, the total global figure for ALS affected individuals is currently estimated at half a million.
Till date, there is no effective cure for ALS. Currently Sanofi-Aventis, the US-based pharmaceutical company, offers the only FDA approved drug, under the name Riltutek, for the disease. With Rilutek's generic invasion approaching in 2012, the growth of ALS market in the future is completely dependent on the status of pipeline drugs as stated by the new market research report on Lou Gehrig's Disease. Lack of treatment options meeting the desired requirements, along with the ALS' orphan drug status and the perceived rapid commercial success once a drug is approved marks significant opportunities for companies to venture the ALS market.
Rilutek is known to only slow down the progression of ALS. A number of approaches focused on finding an effective treatment for ALS are still under investigation and clinical trials. Majority of the approaches employ small molecules, while others are focused on use of biologics including antibodies, peptides, and proteins. Other approaches including cell based therapies have recently evolved for the purpose of clinical testing. The targets undergoing clinical tests include neurotrophic/ neuroprotective therapies, immunomodulators, cellular energy regulators, antioxidants, and glutamate based therapies. Stem cell therapy is one the emerging areas of research, focused on the treatment of ALS. Stem cells play a key role in drug screening, drug delivery, disease modeling and cell therapy for ALS.
Select companies focused on potential ALS treatment approaches include Aeolus Pharmaceuticals, Inc., Ceregene, Inc., CytRx Corporation, Genzyme Corporation, Isis Pharmaceuticals, Knopp Neurosciences, Maas Biolab, NeuroNova AB, Teva Pharmaceutical Industries Ltd., and Trophos SA .
The report titled "Lou Gehrig's Disease: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, competitive scenario, innovative treatment approaches, clinical trials, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, and Rest of World.
For more details about this market research report, please visit -
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/